As part of my NSD Innovation awarded funds (95470 Powell Innovation: charge code N38540) one my deliverables was a review article for journal submission summarizing my work on this project. My NSD Innovation project is expressing Ebola antibodies in tobacco plants. I've attached abstract below Title: From pandemic preparedness to biofuel production: tobacco finds its biotechnology niche in North America Abstract: Abstract: In 2012 scientists funded by the U.S. Defense Advanced Research Projects Agency (DARPA) produced 10 million doses of influenza vaccine in tobacco in a milestone deadline of one month. Recently the experimental antibody cocktail Zmapp?, also produced in tobacco, has shown promise as an emergency intervention therapeutic against Ebola. These two examples showcase how collaborative efforts between government, private industry and academia are applying plant biotechnology to combat pathogenic agents. Opportunities now exist repurposing tobacco expression systems for exciting new applications in synthetic biology, biofuels production and industrial enzyme production. Lastly, as plant-produced biotherapeutics become more mainstream, government funding agencies need to be cognizant of the idea that many plant-produced biologicals are often safer, cheaper and just as efficacious as their counterparts that are produced using traditional expression systems.